Turn Therapeutics Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
TTRX Nasdaq 2830 turntherapeutics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Turn Therapeutics Inc.

Turn Therapeutics to Ring the Nasdaq Closing Bell on Monday, August 10, 2026 - Jul 28th, 2026 6:01 am
Turn Therapeutics Refines GX-03 Eczema Trial After Interim Data, Eyes 2026 Readout - Jul 11th, 2026 11:02 am
Turn Therapeutics’ stock jumps on AD data and trial expansion - Jul 8th, 2026 5:17 am
Turn Therapeutics Completes Interim Phase 2 Review; Expands GX-03 Study in Atopic Dermatitis - Jul 7th, 2026 6:56 am
Turn Therapeutics Announces Final Stage 2 Design and Data-Driven Expansion of GX-03 Phase 2 Program in Atopic Dermatitis - Jul 7th, 2026 6:05 am
Turn Therapeutics to Host Webcast Presenting Comprehensive Interim Analysis and Optimized Stage 2 Design for GX-03 in Atopic Dermatitis - Jul 6th, 2026 2:01 pm
Turn Therapeutics Talks GX-03 Phase II Eczema Data Timeline and Non-Systemic Topical Strategy - Mar 1st, 2026 11:08 pm